Comprehensive analysis of tissue-derived small extracellular vesicles transcriptomic and extensively targeted lipidomics from patients with high-grade serous ovarian cancer

Quick Facts

  • Publication title: Comprehensive analysis of tissue-derived small extracellular vesicles transcriptomic and extensively targeted lipidomics from patients with high-grade serous ovarian cancer
  • Journal: BMC Cancer
  • Year: 2026
  • DOI: 10.1186/s12885-026-15698-9
  • PMID/PMCID: 41680643; PMC13011482

Research overview

The study found that the expression of RMRP was positively correlated with neutrophils. CONCLUSION: These findings revealed the Ti-sEVs transcriptome and extensively targeted lipidome characteristics from ovarian cancer patients, and comprehensive analysis showed that RMRP has the potential to become a promising prognostic biomarker candidate.

Key findings

BACKGROUND: Tissue-derived small extracellular vesicles (Ti-sEVs) are critical components of the tumor microenvironment.

Nonetheless, the biological functions and potential clinical significance of Ti-sEVs lncRNAs and mRNAs in ovarian cancer have not been studied.

METHODS: We collected 5 high-grade serous ovarian cancer specimen, 5 benign ovarian tumors, and 5 normal ovarian tissue specimens.

Ti-sEVs were isolated, and high-throughput sequencing of lncRNA and mRNA and lipid metabolites of the three groups were performed.

Echo Biotech Role

Echo Biotech contributed EV isolation and purification, EV characterization, lncRNA/mRNA sequencing, EV metabolomics/lipidomics; the study also used or cited Exosupur®.

Related platforms: Exoomics®, Research Reagents & Tools

Related services and capabilities: Tissue EV Isolation & Purification, EV Basic Characterization (TEM/NTA/WB), EV lncRNA/mRNA Sequencing, EV Metabolomics/Lipidomics, Research Reagent / Product Supply

Related products or reagents: Exosupur® EV Isolation/Purification Kit

References

Original publication: Comprehensive analysis of tissue-derived small extracellular vesicles transcriptomic and extensively targeted lipidomics from patients with high-grade serous ovarian cancer BMC cancer. 2026. DOI: 10.1186/s12885-026-15698-9. PMID/PMCID: 41680643; PMC13011482.